Christopher C. Lindsey earned his Ph.D. in organic chemistry from the University of California, Santa Barbara, and completed his postdoctoral work at the University of Texas Southwestern Medical Center, Dallas. His career as a medicinal chemist started by studying novel small molecules that had anti-virulence properties for antibiotic-related pathogens. After moving to Charleston, South Carolina, he worked concurrently as director of chemistry for both MitoChem Therapeutics Inc., and MitoHealth Inc.; both companies focus on novel chemical probes that alleviate oxidative stress-mediated pathways. One of his major accomplishments during his tenure at MitoChem was the development of a preclinical candidate to treat retinitis pigmentosa, a rare form of progressive blindness. He also served as a visiting assistant professor at the Medical University of South Carolina, where he worked on new chemotherapies targeting triple-negative breast cancer exploiting green chemistry techniques. He has 13 years of industrial experience and enjoys applying that knowledge base to his work as a program official in the Contraception Research Branch at NICHD.